Cytokine profiling in serum-derived exosomes isolated by different methods

Hae Hyun Jung1, Ji-Yeon Kim2,3, Ji Eun Lim2 & Young-Hyuck Im1,2,3*

Exosomes in blood play an important role in cell-to-cell signaling and are a novel source of biomarkers for the diagnosis and prognosis of diseases. Recently, evidence has accumulated that cytokines are released from encapsulated exosomes and are capable of eliciting biological effects upon contact with sensitive cells. However, there is currently limited information on exosome isolation methods for cytokine research. In this study, we evaluated three exosome isolation methods for their usability, yield, purity, and effectiveness in subsequent cytokine profiling. We found that ultracentrifugation (UC) and Exoquick (EQ), but not exoEasy, yielded appropriate exosome sizes, and EQ had higher exosome extraction efficiency than the other two methods. Although UC generated markedly fewer particles than EQ, it yielded a relatively high purity. Next, we performed a multiplex assay with the ProcartaPlex Immune Monitoring 65-Plex Panel to determine the feasibility of these methods for cytokine profiling. The results indicated significant differences among isolation methods when analyzing exosomal cytokine profiles. We further investigated the changes of exosomal cytokines according to breast cancer progression in triple-negative breast cancer. We found significantly decreased concentrations of MIP-3 alpha, IL-23, M-CSF, Eotaxin-3, BLC, SDF-1 alpha, IL-2R, MDC, FGF-2, IL-22, and IL-31 in exosomes from metastatic breast cancer (MBC) patients.

Bidirectional communication between cells and their microenvironment is critical for maintenance of the body in both physiological and pathological conditions. In addition to traditional soluble factors (chemokines, cytokines, growth factors), a growing body of evidence indicates that extracellular vesicles (EVs) play an important role in cell–cell communication1. Extracellular vesicles (EVs), which are highly heterogeneous, comprise exosomes, shed microvesicles (sMVs), and apoptotic bodies classified by their size, density, and origin2. Exosomes, small microvesicles of 30–150 nm with endosomal origin, are produced by most cells and are actively released by fusion of the microvesicular bodies with the plasma membrane3,4. They carry diverse and complex cargo molecules, such as nucleic acids (DNAs, RNAs), lipids, and proteins, and play an important role in intercellular communication by serving as a carrier for the transfer of these bioactive cargoes between cells. Particularly in cancer, exosomes can take part in the modification of the tumor microenvironment, favoring tumor progression and metastasis5,6. Moreover, exosomes are emerging as potential diagnostic, prognostic, and predictive biomarkers for disease status and treatment outcomes7–9.

Cytokines are small proteins secreted by cells that have a specific role in the interaction and communication between cells. Cytokines are widely recognized as crucial factors in cancer development and therapeutic resistance10,11. Several studies have reported that exosomes deliver cytokines such as TGF-β, TNF-α, IL-6, IL-8, and IL-10 to the recipient cells, leading to development and progression of cancer and drug resistance12–16. These studies suggest that exosome-associated cytokines (exosomal cytokines) could be novel biomarkers.

The isolation and characterization of pure exosomes is critical to the understanding of their biological mechanisms. Various methods based on different principles have been developed for exosome isolation. However, the most effective approach for exosome isolation is not yet well established. The recommendations in the guidelines of the International Society for Extracellular Vesicles (ISEV) are not definite and leave extracellular vesicle (EV) isolation to the investigators’ discretion17.

1Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul 06351, Korea. 2Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351, Korea. 3Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. *email: yh00.im@samsung.com
from serum or plasma is especially problematic because of the small volume available, its high viscosity, and its high concentration of proteins and lipoproteins. For these reasons, it is very important to find a suitable exosome isolation method and identify its potential for analysis of exosomal cytokine biomarkers.

Here, we isolated exosomes from pooled serum of breast cancer patients (N = 30) using three different techniques: ultracentrifugation and two commercial kits, exoEasy (EE; membrane affinity spin column method) and ExoQuick (EQ; polymer-based precipitation). We characterized the size and yield of enriched exosomes using Nanoparticle Tracking Analysis (NTA) and ExoView, then determined the purity of the exosomes using their protein concentration by silver stain and Western blot. We then analyzed their cytokine content using a multiplex assay with the ProcartaPlex Immune Monitoring 65-Plex Panel. We further evaluated exosomal cytokines as potential biomarkers in breast cancer. We compared the exosomal and serum cytokine changes between ductal carcinoma in situ (DCIS), early breast cancer (EBC), and advanced metastatic breast cancer (MBC) with the triple-negative subtype.

Results

Characterization of isolated exosomes. Exosomes were prepared from the pooled serum using three methods: differential ultracentrifugation (UC), exoEasy kit (EE), and ExoQuick solution (EQ). To evaluate the size distribution, exosomes isolated from different methods were subjected to NTA, which revealed that the size distribution curve of the EE method was broader than those of the UC and EQ methods (Fig. 1a). All the exosome preparations from the UC and EQ methods showed the accepted size range (30–150 nm), but not those from the EE method. The EE method exhibited the largest mode size compared to the UC and EQ methods (mean ± SD; EE 172.6 ± 25.7 nm > UC 81.9 ± 6.5 nm > EQ 77.7 ± 8.6 nm). Further analysis of the concentration of exosomes by NTA revealed that the EQ method is appropriate for isolation of larger numbers of particles.
(5.5 × 10^{11} \text{ particles/mL}), followed by the EE method (7.6 × 10^{9} \text{ particles/mL}). Enrichment of exosomes by UC yielded the lowest concentration (1.5 × 10^{9} \text{ particles/mL}) (Fig. 1b).

To obtain more elaborate results, exosome fractions were analyzed by SP-IRIS using the ExoView platform in order to quantify exosomes depending on their expression of marker proteins. Exosomes were captured by antibodies targeting the common exosome markers CD9, CD63, and CD81 and subsequently imaged and quantified. Overall, the NTA results correlated well with the ExoView results, but the exosome size measured by ExoView was smaller than the value measured by NTA. Similar to NTA, the exosome size distribution of the EE method was broader and more heterogeneous than those of the UC and EQ methods (Fig. 1c). Captured exosome counts were highest with the EQ method. More exosomes were captured by CD9 than by CD63 and CD81 with the UC method, and less exosomes were captured by CD63 than by CD9 and CD81 with the EE method. With the EQ method, the numbers of exosomes captured by the three markers were similar (Fig. 1d).

ExoView analysis showed that CD81-captured exosomes had low CD63 co-expression, while exosomes co-expressing CD63 and CD9 were relatively high in all three methods (Fig. 1e).

In summary, among the three methods, UC and EQ were most appropriate for selecting exosome size, and EQ showed the highest exosome extraction efficiency when isolating a large number of particles. We confirmed that exosome size, exosome extraction efficiency, and expression of exosome marker proteins differ according to extraction method.

**Exosome purity.** We measured the amount of protein present in the exosome samples to evaluate their purity. EQ yielded the highest protein content (18,871 ± 147 μg/mL), followed by EE (136 ± 1 μg/mL). The amount of protein determined in exosome fractions obtained by UC was the lowest (8 ± 0.2 μg/mL) (Fig. 2a). For measurement of particle purity, the particle-protein ratio^19 was used. The ratio was significantly lower for EE and EQ than for UC, indicating co-isolation of serum proteins in EE and EQ (Fig. 2b). Protein yield, expressed as relative protein amount per 10^8 particles, was 3.6- and 6.8-fold respectively higher in exosome preparations from EE and EQ, respectively, compared to UC (data not shown). These samples were tested for protein distribution by silver stain. Albumin, the most abundant plasma protein, was readily detectable in EE and EQ preparations (Supplementary Fig. 1). To further assess the purity, western blot analysis was performed with equal protein loading to allow direct evaluation of the exosome sample purity by comparing the enrichment of proteins regarded as an exosomal marker (CD63) and albumin. Accordingly, we detected a dramatic enrichment of CD63 in exosomes isolated by UC but not from EE and EQ (Fig. 2d). The high protein content and the low particle-protein ratio together with the low levels of exosome markers isolated from the EE and EQ methods suggest co-isolation of contaminating serum proteins.

**Profiles of cytokines from serum and exosomes.** To examine the variations in cytokine expression with different exosome isolation methods, we performed a multiplex assay using the ProcartaPlex Immune Monitoring 65-Plex Panel. Intact exosomes, lysed exosomes, and serum were used for the assay. The amounts of cytokines were calculated by multiplication of the ratio of starting serum volume. The heatmap showed that cytokine profiling was different according to the isolation method. In the UC and EQ methods, cytokines were released more from lysed exosomes than from intact exosomes, whereas in the EE method, relatively small amounts of cytokines were released from both types of exosomes in similar amounts (Fig. 3a, Supplementary Table 1).
Analysis of individual cytokines in exosomes isolated by UC revealed that 12 cytokines, IL-2R, APRIL, SDF-1 alpha, TWEAK, MDC, VEGF-A, IL-22, IL-23, M-CSF, FGF-2, IL-4, and G-CSF, were found in greater levels in lysed exosomes than in intact exosomes. In the EE method, cytokine levels, except TWEAK and APRIL, were very low in both types of exosome. Analysis of cytokines in exosomes isolated by EQ revealed that 13 cytokines, IL-23, M-CSF, IL-31, TNF beta, IL-2R, FGF-2, IL-4, Gro-alpha, IL-9, IL-8, Eotaxin-3, IL-1 alpha, and G-CSF, were found in lysed exosomes. However, other cytokines were detected in intact as well as lysed exosomes, indicating co-isolation of blood proteins (Fig. 3b).

We also compared exosomal cytokine profiling using data normalized by the number of isolated exosomes using different exosome isolation methods. The heatmap showed that cytokine expressions per exosomal particle were the highest in the UC method (Supplementary Fig. 2). Based on the above results, we used the UC method in our further studies to avoid confounding results regarding exosome biomarker candidates.

Changes of exosome-associated cytokines according to breast cancer types and stages in triple-negative breast cancer. Next, we investigated the possibility of exosome-associated cytokines as prognostic biomarkers in triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype. TNBC is defined by no expression of estrogen receptor (ER) and progesterone receptor (PR), and no amplification or overexpression of HER220. Recent research has demonstrated that TNBC has higher immunogenicity than other subtypes, as it has a significant number of genetic mutations and robust tumor immune cell infiltration21.

Exosomes were isolated from serum obtained from patients with ductal carcinoma in situ (DCIS, n = 9), early breast cancer (EBC, n = 17), and metastatic breast cancer (MBC, n = 17) using the UC method. The clinical information of the patients is summarized in Table 1. Serum and exosomal cytokine levels were determined by a multiplex assay using the ProcartaPlex Immune Monitoring 65-Plex Panel. The values of cytokines were subjected to unsupervised-hierarchical cluster analysis, and the result showed that the serum and lysed exosome samples...
were accurately distinguished based on the samples (Fig. 4a). The Kruskal–Wallis test was used to statistically analyze the values of cytokines. We obtained 13 cytokines differentially expressed among DCIS, EBC, and MBC (Table 2). We found significantly decreased concentrations of MIP-3 alpha, IL-23, M-CSF, Eotaxin-3, BLC, SDF-1 alpha, IL-2R, MDC, FGF-2, IL-22, and IL-31 in MBC patients’ exosomes. In contrast, the concentrations of MCP-1 and MIF increased in MBC patients’ serum (Fig. 4b). Furthermore, we analyzed the variation in serum and exosomal cytokine expression according to stages. We divided patients into a DCIS group (stage 0, n = 9), an early-stage group (stage I/II, n = 8), and an advanced-stage group (stage III, n = 9). Similar to Fig. 4, exosomal cytokine concentrations tended to decrease according to the disease stage of the patient (Fig. 5). However, the results were not statistically significant, possibly due to our small sample size.

|                | DCIS  | EBC  | MBC  |
|----------------|-------|------|------|
|                | n = 9 | n = 17 | n = 17 |
| Age            | Median | 42.50 | 42.50 |
|                | Range | 30-76 | 35-72 |
|                | 33-54 |       |       |
| Histology      | DCIS  | 9     | -     |
|                | IDC   | -     | 17    |
|                | Others| -     | 0     |
| Tumor size     | Tis   | 9     | -     |
|                | T1    | -     | 7     |
|                | T2    | -     | 5     |
|                | T3    | -     | 4     |
|                | T4    | -     | 1     |
|                | Unknown | -     | 0     |
| Lymph nodes    | N0    | 9     | 7     |
|                | N1    | -     | 1     |
|                | N2    | -     | 3     |
|                | N3    | -     | 6     |
|                | Unknown | -     | 2     |
| Nuclear grade  | 1     | 3     | 0     |
|                | 2     | 3     | 5     |
|                | 3     | 3     | 12    |
|                | Unknown | 0     | 2     |
| Histology grade| 1     | -     | 1     |
|                | 2     | -     | 4     |
|                | 3     | -     | 12    |
|                | Unknown | -     | 2     |
| Stage          | 0     | 9     | -     |
|                | I     | -     | 6     |
|                | II    | -     | 2     |
|                | III   | -     | 9     |
|                | IV    | -     | 0     |
| Adjuvant chemotherpy | Yes | -     | 16    |
|                | No    | -     | 1     |
| Adjuvant radiotherapy | Yes | 7     | 15    |
|                | No    | 2     | 2     |
| Overall survival | Alive | 9     | 9     |
|                | Dead  | -     | 8     |
|                |       |       | 13    |

**Table 1.** Patient characteristics.
Discussion

As the potential for clinical applications of exosomes increases, it is crucial to optimize the isolation method in terms of purity, yield, and reproducibility. Despite the recent development of several isolation methods for exosomes, there is still no standardization and new methods are often used without well-organized comparative analysis.

Several studies have attempted to compare the effect of various exosome isolation techniques on downstream analyses. Some groups have conducted comparative studies on different isolation methods regarding their effects on subsequent RNA22–26 and proteomic27,28 analysis. However, there is limited information regarding proper isolation methods for exosomal cytokine analysis. Although Macías et al.29 evaluated six commercial exosome kits, including EQ and EE, for exosomal cytokines in serum, they evaluated only three cytokines (S100A9, CXCL5, and CXCL12) and the methods they used did not include UC, the traditional exosome isolation method.

In this study, we provided a comparative evaluation of three exosome isolation methods for their size, yield, purity, and effects in subsequent cytokine profiling. We isolated exosomes from serum using three different techniques: ultracentrifugation (the most common EV isolation methods), exoEasy (EE; membrane affinity spin column method)30 and ExoQuick (EQ; polymer-based precipitation). The size-exclusion chromatography method was omitted as it requires a second step to concentrate samples, although it can isolate more purified exosomes31.

We characterized the size, yield, and exosome markers of enriched exosomes using Nanoparticle Tracking Analysis (NTA) and ExoView. We found that all methods were appropriate to isolate exosomes, as illustrated by ExoView for exosome markers. All the exosome preparations from the UC and EQ methods showed the accepted size range, but not those from the EE method. The EE-isolated exosomes were a heterogeneous mixture of particles with a larger diameter and broader size range than the UC- and EQ-isolated exosomes. This heterogeneity has been described by other groups32. The EQ method shows the best exosome extraction efficiency. These results
did not test lipoprotein contamination, which has a size in the range of exosomes18. The UC method provided the highest purity, suggesting less protein contamination with this method. However, we found that the UC method is more suitable than the EE and EQ methods for exosomal cytokine studies. Our study is, to the best of our knowledge, the first study that proves the clinical significance of exosomal cytokines in breast cancer. Cytokine expression in breast cancer.

Next, we investigated the changes of exosomal cytokines according to breast cancer types and stages in triple-negative breast cancer (TNBC). Several studies have reported that exosome biomarkers (such as CD44, CD47, CXCR4, Del-1, HER2, and KDR) can be used for early diagnosis and prognosis of breast cancer patients36. However, there are no studies regarding exosomal cytokines as biomarkers in breast cancer. Cytokine expression was evaluated in serum and exosomes isolated from ductal carcinoma in situ (DCIS), early breast cancer (EBC), and advanced metastatic breast cancer (MBC) with the triple-negative subtype. The exosomal cytokine level tended to decrease with the stage of disease (DCIS > EBC > MBC). MBC patients' exosomes had a low concentration of MIP-3 alpha, IL-23, M-CSF, Eotaxin-3, BLC, SDF-1 alpha, IL-2R, MDC, FGF-2, IL-22, and IL-31, suggesting that metastatic disease may be associated with immune suppression related to low exosomal cytokine concentration. These results are consistent with previous reports that the levels of the cytokines IFN-γ, IL-10, and IL-3 were decreased in plasma exosomes from grade 4 GBM (glioblastoma multiforme) patients compared to normal donors37. Unlike exosomes, MBC patients' serum had a high concentration of MCP-1 and MIF, suggesting that high levels of MCP-1 and MIF play an important role in metastasis. Our findings showed the potential role of exosomal cytokines as a blood-based biomarker in more aggressive tumors. Further large-scale studies are needed to prove the usefulness of exosomal-derived cytokines as biomarkers in clinical practice.

In this study, we demonstrated that the exosome isolation method greatly affects the cytokine profile. We also found that the UC method is more suitable than the EE and EQ methods for exosomal cytokine studies. Our results could serve as a guide when selecting exosome isolation methods to find reliable biomarkers in serum. Furthermore, we showed that 11 exosomal cytokines were decreased according to the progression of TNBC. This study is, to the best of our knowledge, the first study that proves the clinical significance of exosomal cytokines in breast cancer.

Table 2. Summary of the statistical significance of all group comparisons. Serum and exosomal cytokines between different groups were analyzed using the Kruskal–Wallis test. P < 0.05 was considered statistically significant. The unit of measurement is in pg/mL. DCIS ductal carcinoma in situ, EBC early breast cancer, MBC metastatic breast cancer.

| Cytokine | DCIS serum (n=9) Mean ± SE | EBC serum (n=17) Mean ± SE | MBC serum (n=17) Mean ± SE | p value | DCIS exosomes (n=9) Mean ± SE | EBC exosomes (n=17) Mean ± SE | MBC exosomes (n=17) Mean ± SE | p value |
|---------|-----------------------------|----------------------------|-----------------------------|---------|-----------------------------|----------------------------|-----------------------------|---------|
| MIP-3 alpha | 15 ± 4.5 | 8 ± 3.3 | 22 ± 7 | 0.118 | 75 ± 20.5 | 75 ± 28.3 | 8 ± 1.5 | 0.001 |
| IL-23 | – | – | – | 1 | 2.506 ± 898.1 | 1,482 ± 590.1 | 185 ± 19.5 | 0.002 |
| M-CSF | – | – | – | 1 | 122 ± 37.1 | 61 ± 16.9 | 11 ± 4.5 | 0.002 |
| Eotaxin-3 | – | – | – | 1 | 47 ± 9.6 | 39 ± 12.7 | 6 ± 0.9 | 0.003 |
| BLC | 183 ± 35 | 156 ± 21.9 | 217 ± 47.2 | 0.500 | 69 ± 12 | 39 ± 5.7 | 33 ± 4.1 | 0.008 |
| SDF-1 alpha | 931 ± 110.3 | 672 ± 29.2 | 752 ± 73.6 | 0.090 | 536 ± 43.7 | 692 ± 51.2 | 439 ± 61 | 0.010 |
| IL-2R | – | – | 25 ± 25.1 | 0.479 | 1825 ± 277 | 998 ± 168.9 | 819 ± 181.8 | 0.012 |
| MDC | 112 ± 13.6 | 92 ± 9.2 | 84 ± 14.6 | 0.279 | 51 ± 13.6 | 25 ± 4.8 | 14 ± 2.5 | 0.012 |
| FGF-2 | – | – | – | 1 | 181 ± 31.8 | 97 ± 20.2 | 79 ± 14.1 | 0.036 |
| IL-22 | – | – | 7 ± 7.4 | 0.479 | 68 ± 17.1 | 35 ± 9.9 | 36 ± 15.5 | 0.041 |
| IL-31 | – | – | – | 1 | 145 ± 38.5 | 57 ± 20.2 | 35 ± 14.9 | 0.044 |
| APRIL | 1777 ± 619.7 | 819 ± 89.9 | 876 ± 116.3 | 0.103 | 1,071 ± 370.2 | 608 ± 86.6 | 457 ± 98.9 | 0.056 |
| G-CSF | 0 ± 0 | 1 ± 2 | 0 ± 0 | 0.479 | 439 ± 76.5 | 290 ± 60 | 217 ± 29.3 | 0.057 |
| MCP-1 | 52 ± 10.5 | 38 ± 4.4 | 80 ± 13.3 | 0.006 | 5 ± 1 | 2 ± 0.6 | 1 ± 0.5 | 0.010 |
| MIF | 36 ± 3.8 | 41 ± 2.1 | 49 ± 2.7 | 0.013 | 15 ± 2.3 | 15 ± 3.1 | 11 ± 1.2 | 0.304 |
Material and methods

Patients and blood samples. All patients were diagnosed with breast cancer at the Samsung Medical Center between 2008 and 2010. Pooled serum samples from breast cancer patients (N = 30) were provided by Samsung Medical Center BioBank. Forty-three samples were analyzed in this study, including samples from patients diagnosed with DCIS (n = 9), EBC (n = 17), and MBC (n = 17) with triple-negative subtype. DCIS and EBC samples were collected prior to surgical resection and chemotherapy and were provided by Samsung Medical Center BioBank. Patients with MBC received palliative chemotherapy with a median of 1.4 regimens (range, 1–3 regimens) before their enrollment. Blood samples were incubated for 30 min in room temperature for clotting, then centrifuged for 20 min at 3,000 rpm. Serum was isolated and stored at −80 °C until analysis. All patients provided written informed consent to access their blood and review their medical records. The study was approved by the ethics committee of Samsung Medical Center (IRB No: 2010-08-077, 2017-12-068) and was conducted in accordance to the Declaration of Helsinki. All experiments were performed in accordance with relevant guidelines and regulations.

Exosome isolation from serum. Exosomes were isolated from serum samples using differential centrifugation and two commercial kits: ExoQuick Serum Exosome Precipitation Solution (System Biosciences, Palo Alto, CA, USA) and exoEasy kit (Qiagen GmbH, Hilden, Germany). Serum samples were centrifuged at 2,000×g for 10 min and 10,000×g for 30 min at 4 °C to thoroughly remove cellular debris. Next, supernatants were filtered through a 0.2 μm pore size filter to exclude particles > 200 nm in diameter. For exosome isolation by differential ultracentrifugation, the filtered supernatant was collected into ultracentrifuge tubes and centrifuged in an Optima MAX-XP ultracentrifuge with an MLA-130 rotor (Beckman Coulter, Jersey City, NJ, USA) at 100,000 g for 1 h at 4 °C. The pellets were washed with PBS, ultracentrifuged again, and resuspended in PBS. For exosome

Figure 5. Serum and exosomal cytokine expression according to each stage in patients with DCIS and EBC. Exosomes were isolated from 250 μL of patients' sera by serial ultracentrifugation. Cytokines were detected in serum and lysed exosomes by multiplex assay. Scatter plots compare serum and exosomal cytokine concentrations in patients with DCIS (stage 0, n = 9), early-stage breast cancer (stage I/II, n = 8), and advanced-stage breast cancer (stage III, n = 9). The statistical analysis was performed by Mann–Whitney–U test analysis. p < 0.05 was considered statistically significant.
isolation by ExoQuick and exoEasy, the two commercial kits were used according to the manufacturers’ instructions. Exosome preparations were conserved at −80 °C for later use.

**Nanoparticle tracking analysis (NTA).** The size distribution and concentration of the serum-derived exosomes were analyzed by NTA using a NanoSight model NS300 equipped with a red laser and a SCMOS camera (Malvern Instruments, Malvern, UK). The samples were diluted in 1 ml PBS and mixed well, and the diluted samples were then injected into the laser chamber. The following settings were used for data acquisition: camera level 14, acquisition time 30 s, and detection threshold 3. Data analysis was performed with the NTA v3.2 software. Three recordings were performed for each sample.

**Nanoview analysis.** Exosomes were detected using the ExoView Tetraspanin chip (ExoView, Boston, MA, USA) arrayed with antibodies against proteins CD81, CD63, and CD9. Mouse IgG1 was used as a negative control. Thirty-five µL of sample was dropped onto the chip surface and incubated overnight. After washing, the chips were treated with ExoView Tetraspanin Labelling ABs (EV-TC-AB-01), including CD9/ALEXA 488, CD81/ALEXA 555, and CD63/ALEXA 647, for co-localization tests in order to characterize the sub-populations on the surface of exosomes. The chips were then imaged with the ExoView R100 reader (ExoView) through the Single Particle Interferometric Reflectance Imaging Sensor (SP-IRIS) technology using the ExoScan v0.998 (ExoView) acquisition software. The data was analyzed using ExoViewer v0.998 with sizing thresholds set from 50 to 200 nm diameter.

**Protein isolation and quantification.** Intact exosomes resuspended in PBS were lysed with 10× RIPA buffer (Cell Signaling Technology, Danvers, MA, USA). Protein quantification of the lysed exosomes was performed using the Micro BCA Protein Assay Reagent Kit (Thermo Scientific, Waltham, MA, USA). The purity of exosome preparations was determined by calculating the ratio between particle number, determined by NTA, and protein concentration measured through Micro BCA assay. For silver staining, proteins were separated on 10% SDS-PAGE gels and visualized using a Pierce silver stain kit per the manufacturer’s instructions.

**Western blot.** Total exosome proteins were isolated with RIPA buffer (Cell Signaling Technology). 10 µg of proteins per sample were separated by a NuPAGE 4–12% Bis–Tris gel (Invitrogen, Waltham, MA, USA) and transferred onto a PVDF membrane (Merck Millipore, Burlington, MA, USA). Membranes were blocked in 5% Bovine Serum Albumin in TBS-T for 2 h at room temperature and then incubated with primary antibodies against CD63 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and albumin (Cell Signaling Technology) overnight at 4 °C with gentle rocking. Membranes were washed, and HRP-conjugated antibodies were added for 1 h at room temperature. Detection was performed using enhanced chemiluminescence (ECL) reagents (Invitrogen) according to the manufacturer’s guidelines.

**Multiplex immunoassay.** Intact exosomes, lysed exosomes, and serum samples were collected and stored at −80 °C until analysis. Sample aliquots had not been previously thawed before use in the multiplex chemokine assay. We measured the levels of APRIL, BAFF, BLC, CD30, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, FGF-2, Fractalkine, G-CSF, GM-CSF, GROα, HGF, IFN-α, IFN-β, IFN-γ, IL-10, IL-12p70, IL-13, IL-15, IL-17A, IL-18, IL-1α, IL-1β, IL-2, IL-20, IL-21, IL-22, IL-23, IL-27, IL-2R, IL-3, IL-31–IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IP-10, I-TAC, IFN-γ, MCP-1, MCP-2, MCP-3, M-CSF, MDC, MIF, MIP-1α, MIP-1β, MIP-3α, MMP-1, NGF beta, SCF, SDF-1α, TNF-β, TNF-α, TNF-R2, TRAIL, TSLP, TWEAK, and VEGF-A with the ProcartaPlex Human Immune Monitoring 65-Plex Panel (Invitrogen) using the Bio-Plex200 (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer’s instructions. Full names of cytokines are presented in Supplementary Table 2.

**Statistical analysis.** All statistical analyses were performed using SPSS 20.0 software (IBM, USA), and the graphs were generated using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA). The comparisons between multiple groups were determined by analysis of variance (ANOVA) for parametric data and the Kruskal–Wallis test for nonparametric data. A value of P < 0.05 was considered statistically significant.

Received: 26 February 2020; Accepted: 14 July 2020
Published online: 21 August 2020

**References**

1. Pitt, J. M., Kroemer, G. & Zitvogel, L. Extracellular vesicles: masters of intercellular communication and potential clinical interventions. *J. Clin. Invest.* 126, 1139–1143. https://doi.org/10.1172/jci87316 (2016).
2. van Niel, G., D’Angelo, G. & Raposo, G. Shedding light on the cell biology of extracellular vesicles. *Nat. Rev. Mol. Cell Biol.* 19, 213–228. https://doi.org/10.1038/nrm.2017.125 (2018).
3. Thery, C., Zitvogel, L. & Amigorena, S. Exosomes: composition, biogenesis and function. *Nat. Rev. Immunol.* 2, 569–579. https://doi.org/10.1038/nri855 (2002).
4. Raposo, G. & Stoorvogel, W. Extracellular vesicles: exosomes, microvesicles, and friends. *J. Cell Biol.* 200, 373–383. https://doi.org/10.1083/jcb.201211138 (2013).
5. Becker, A. et al. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. *Cancer Cell* 30, 836–848. https://doi.org/10.1016/j.ccell.2016.10.009 (2016).
6. Raposo, G. & Stoorvogel, W. Extracellular vesicles: exosomes, microvesicles, and friends. *Nat. Rev. Mol. Cell Biol.* 17, 571–583. https://doi.org/10.1038/nrm.2017.125 (2018).
7. Thery, C., Zitvogel, L. & Amigorena, S. Exosomes: composition, biogenesis and function. *Nat. Rev. Immunol.* 2, 569–579. https://doi.org/10.1038/nri855 (2002).
8. Raposo, G. & Stoorvogel, W. Extracellular vesicles: exosomes, microvesicles, and friends. *J. Cell Biol.* 200, 373–383. https://doi.org/10.1083/jcb.201211138 (2013).
9. Becker, A. et al. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. *Cancer Cell* 30, 836–848. https://doi.org/10.1016/j.ccell.2016.10.009 (2016).
6. Nogue, L., Benito-Martin, A., Herguita-Redondo, M. & Peinado, H. The influence of tumour-derived extracellular vesicles on local and distal metastatic dissemination. Mol. Asp. Med. 60, 15–26. https://doi.org/10.1016/j.mam.2017.11.012 (2018).

7. Ruhn, O. & Meehan, K. Tumor-derived extracellular vesicles as a novel source of protein biomarkers for cancer diagnosis and monitoring. Proteomics 19, e1800155. https://doi.org/10.1002/pmic.201800155 (2019).

8. Urabe, F. et al. Extracellular vesicles as biomarkers and therapeutic targets for cancer. Am. J. Physiol. Cell Physiol. 318, C29–C39. https://doi.org/10.1152/ajpcell.00280.2019 (2020).

9. Hesari, A. et al. Tumor-derived exosomes: potential biomarker or therapeutic target in breast cancer. J. Cell Biochem. 119, 4236–4240. https://doi.org/10.1002/jcb.26364 (2018).

10. Yao, M., Brummer, G., Acevedo, D. & Cheng, N. Cytokine regulation of metastasis and tumorigenicity. Adv. Cancer Res. 132, 265–367. https://doi.org/10.1016/bs.acr.2016.05.005 (2016).

11. Tan, C. et al. Cytokine-mediated therapeutic resistance in breast cancer. Cytokine 108, 151–159. https://doi.org/10.1016/j.cyto.2018.03.020 (2018).

12. Soderberg, A., Barral, A. M., Soderstrom, M., Sander, B. & Rosen, A. Redox-signaling transmitted in trans to neighboring cells by melanoma-derived TNF-containing exosomes. Free Radic. Biol. Med. 43, 99–99. https://doi.org/10.1016/j.freeradbiomed.2007.03.026 (2007).

13. Roccaro, A. M. et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Investig. 123, 1542–1555. https://doi.org/10.1172/JCI66517 (2013).

14. Kucharzewska, P. et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc. Natl. Acad. Sci. U. S. A. 110, 7312–7317. https://doi.org/10.1073/pnas.1209988110 (2013).

15. Wang, Y. et al. The regulation of cancer cell migration by lung cancer cell-derived exosomes through TGF-β and IL-10. Oncol. Lett. 11, 1527–1530. https://doi.org/10.3892/ol.2015.4044 (2016).

16. Martinez, V. G. et al. Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles. Oncotarget 6, e136250. https://doi.org/10.18698/2016.0242X.2017.136250 (2017).

17. Thery, C. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 7, 1535750. https://doi.org/10.1080/20010378.2018.1535750 (2018).

18. Yuana, Y. et al. Cryo-electron microscopy of extracellular vesicles in fresh plasma. J. Extracell. Vesicles https://doi.org/10.3402/jev.v20i2.12494 (2013).

19. Webber, J. & Clayton, A. How pure are your vesicles? J. Extracell. Vesicles https://doi.org/10.3402/jev.v2i0.19861 (2013).

20. Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938–1948. https://doi.org/10.1056/NEJMra1001389 (2010).

21. Denkert, C., Liedtke, C., Tutt, A. & von Minckwitz, G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet (London, England) 389, 2430–2442. https://doi.org/10.1016/S0140-6736(16)32454-0 (2017).

22. Ding, M. et al. Comparison of commercial exosome isolation kits for circulating exosomal microRNA profiling. Anal. Bioanal. Chem. 410, 3805–3814. https://doi.org/10.1002/abcc.201802581 (2018).

23. Van Deun, J. et al. The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. J. Extracell. Vesicles https://doi.org/10.3402/jev.v3.24858 (2014).

24. Andreu, Z. et al. Comparative analysis of EV isolation procedures for miRNAs detection in serum samples. J. Extracell. Vesicles 5, 31655. https://doi.org/10.3402/jev.v5.31655 (2016).

25. Helwa, I. et al. A comparative study of serum exosome isolation using differential ultracentrifugation and three commercial reagents. PLoS ONE 12, e0170628. https://doi.org/10.1371/journal.pone.0170628 (2017).

26. Yang, Y. T. et al. Comparison of isolation methods of exosomes and exosomal RNA from cell culture medium and serum. Int. J. Mol. Med. 40, 834–844. https://doi.org/10.3892/ijmm.2017.3080 (2017).

27. Kalra, H. et al. Comparative proteomics evaluation of plasma exosome exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics 13, 3354–3364. https://doi.org/10.1002/pmic.201300282 (2013).

28. Patel, G. K. et al. Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications. Sci. Rep. 9, 5335. https://doi.org/10.1038/s41598-019-41800-z (2019).

29. Macias, M. et al. Comparison of six commercial serum exosome isolation methods suitable for clinical laboratories. Effect in cytokine analysis. Clin. Chem. Lab. Med. 57, 1539–1545. https://doi.org/10.1515/cclm-2018-1297 (2019).

30. Enderle, D. et al. Characterization of RNA from exosomes and other extracellular vesicles isolated by a novel spin column-based method. PLoS ONE 10, e0136133. https://doi.org/10.1371/journal.pone.0136133 (2015).

31. Mol, E. A., Goumans, M. J., Doevendans, P. A., Sluijter, J. P. G. & Vande Wouwer, P. Higher functionality of extracellular vesicles isolated using size-exclusion chromatography compared to ultracentrifugation. Nanomedicine 13, 2061–2065. https://doi.org/10.1016/j.nano.2017.03.011 (2017).

32. Stranska, R. et al. Comparison of membrane affinity-based method with size-exclusion chromatography for isolation of exosome-like vesicles from human plasma. J. Transl. Med. 16, 1. https://doi.org/10.1186/s12967-017-1374-6 (2018).

33. Serrano-Pertierra, E. et al. Characterization of plasma-derived extracellular vesicles isolated by different methods: a comparison study. Bioengineering (Basel) https://doi.org/10.3390/bioengineering6010008 (2019).

34. Fitzgerald, W. et al. A system of cytokins encapsulated in extracellular vesicles. Sci. Rep. 8, 8973. https://doi.org/10.1038/s41598-018-27190-x (2018).

35. Ciyertkovic, A., Lotvall, J. & Lasser, C. The influence of rotor type and centrifugation time on the yield and purity of extracellular vesicles. J. Extracell. Vesicles https://doi.org/10.3402/jev.v8s.v3.23111 (2014).

36. Wang, M. et al. Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients. Clin. Transl. Oncol. 20, 906–911. https://doi.org/10.1007/s12994-017-1805-0 (2018).

37. Cumba Garcia, L. M., Peterson, T. E., Cepeda, M. A., Johnson, A. J. & Parney, I. F. Isolation and analysis of plasma-derived exosomes in patients with glioma. Front. Oncol. 9, 651. https://doi.org/10.3389/fonc.2019.00651 (2019).

Acknowledgements
This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2018R1D1A1B07047723) and NRF-2019R1A6A3A13095111. The biospecimens for this study were provided by Samsung Medical Center BioBank.

Author contributions
Y.-H.I. and H.H.J conceived the project and designed the experiments. H.H.J. executed the experiments and analyzed the data; J.-Y.K. and J.E.L. executed data curation; H.H.J. and J.-Y.K. wrote the manuscript; Y.-H.I. supervised the entire research. All authors read and approved the final manuscript.
Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-70584-z.

Correspondence and requests for materials should be addressed to Y.-H.I.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020